Optic neuropathy and amiodarone therapy

L. A. Feiner, B. R. Younge, F. J. Kazmier, B. H. Stricker, Frederick (Fritz) Fraunfelder

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Optic neuropathy has been diagnosed in several amiodarone-treated patients, including the 13 patients described in this report. The clinical severity of this drug-related optic neuropathy is milder than that characteristically described in anterior ischemic optic neuropathy. The incidence of occurrence was significantly higher than that found in an age-matched general population sample. Whether this result was due solely to amiodarone therapy, to the underlying poor health of these patients, or to a combination of these two factors is uncertain. The findings in this study prompt us to recommend that all patients who receive amiodarone undergo complete ophthalmologic examinations, including careful evaluation of the ocular fundus regularly during such therapy. Appearance of optic neuropathy is probably a relative indication for discontinuing the use of the drug, in the hopes of avoiding bilateral involvement or perhaps recovering vision. The risks of complications of amiodarone treatment must be weighed against the benefit of therapy in patients whose lives are threatened by cardiac arrhythmias. On the basis of this study, the benefits of treatment seem to outweigh the small risk of optic neuropathy. No randomized study has been undertaken to determine the true incidence of complications associated with this medication and at this time could not be justified.

Original languageEnglish (US)
Pages (from-to)702-717
Number of pages16
JournalMayo Clinic Proceedings
Volume62
Issue number8
StatePublished - 1987

Fingerprint

Optic Nerve Diseases
Amiodarone
Ischemic Optic Neuropathy
Therapeutics
Incidence
Pharmaceutical Preparations
Cardiac Arrhythmias
Health
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feiner, L. A., Younge, B. R., Kazmier, F. J., Stricker, B. H., & Fraunfelder, F. F. (1987). Optic neuropathy and amiodarone therapy. Mayo Clinic Proceedings, 62(8), 702-717.

Optic neuropathy and amiodarone therapy. / Feiner, L. A.; Younge, B. R.; Kazmier, F. J.; Stricker, B. H.; Fraunfelder, Frederick (Fritz).

In: Mayo Clinic Proceedings, Vol. 62, No. 8, 1987, p. 702-717.

Research output: Contribution to journalArticle

Feiner, LA, Younge, BR, Kazmier, FJ, Stricker, BH & Fraunfelder, FF 1987, 'Optic neuropathy and amiodarone therapy', Mayo Clinic Proceedings, vol. 62, no. 8, pp. 702-717.
Feiner LA, Younge BR, Kazmier FJ, Stricker BH, Fraunfelder FF. Optic neuropathy and amiodarone therapy. Mayo Clinic Proceedings. 1987;62(8):702-717.
Feiner, L. A. ; Younge, B. R. ; Kazmier, F. J. ; Stricker, B. H. ; Fraunfelder, Frederick (Fritz). / Optic neuropathy and amiodarone therapy. In: Mayo Clinic Proceedings. 1987 ; Vol. 62, No. 8. pp. 702-717.
@article{9fed15f1f8e94c2182f616681164ad0d,
title = "Optic neuropathy and amiodarone therapy",
abstract = "Optic neuropathy has been diagnosed in several amiodarone-treated patients, including the 13 patients described in this report. The clinical severity of this drug-related optic neuropathy is milder than that characteristically described in anterior ischemic optic neuropathy. The incidence of occurrence was significantly higher than that found in an age-matched general population sample. Whether this result was due solely to amiodarone therapy, to the underlying poor health of these patients, or to a combination of these two factors is uncertain. The findings in this study prompt us to recommend that all patients who receive amiodarone undergo complete ophthalmologic examinations, including careful evaluation of the ocular fundus regularly during such therapy. Appearance of optic neuropathy is probably a relative indication for discontinuing the use of the drug, in the hopes of avoiding bilateral involvement or perhaps recovering vision. The risks of complications of amiodarone treatment must be weighed against the benefit of therapy in patients whose lives are threatened by cardiac arrhythmias. On the basis of this study, the benefits of treatment seem to outweigh the small risk of optic neuropathy. No randomized study has been undertaken to determine the true incidence of complications associated with this medication and at this time could not be justified.",
author = "Feiner, {L. A.} and Younge, {B. R.} and Kazmier, {F. J.} and Stricker, {B. H.} and Fraunfelder, {Frederick (Fritz)}",
year = "1987",
language = "English (US)",
volume = "62",
pages = "702--717",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Optic neuropathy and amiodarone therapy

AU - Feiner, L. A.

AU - Younge, B. R.

AU - Kazmier, F. J.

AU - Stricker, B. H.

AU - Fraunfelder, Frederick (Fritz)

PY - 1987

Y1 - 1987

N2 - Optic neuropathy has been diagnosed in several amiodarone-treated patients, including the 13 patients described in this report. The clinical severity of this drug-related optic neuropathy is milder than that characteristically described in anterior ischemic optic neuropathy. The incidence of occurrence was significantly higher than that found in an age-matched general population sample. Whether this result was due solely to amiodarone therapy, to the underlying poor health of these patients, or to a combination of these two factors is uncertain. The findings in this study prompt us to recommend that all patients who receive amiodarone undergo complete ophthalmologic examinations, including careful evaluation of the ocular fundus regularly during such therapy. Appearance of optic neuropathy is probably a relative indication for discontinuing the use of the drug, in the hopes of avoiding bilateral involvement or perhaps recovering vision. The risks of complications of amiodarone treatment must be weighed against the benefit of therapy in patients whose lives are threatened by cardiac arrhythmias. On the basis of this study, the benefits of treatment seem to outweigh the small risk of optic neuropathy. No randomized study has been undertaken to determine the true incidence of complications associated with this medication and at this time could not be justified.

AB - Optic neuropathy has been diagnosed in several amiodarone-treated patients, including the 13 patients described in this report. The clinical severity of this drug-related optic neuropathy is milder than that characteristically described in anterior ischemic optic neuropathy. The incidence of occurrence was significantly higher than that found in an age-matched general population sample. Whether this result was due solely to amiodarone therapy, to the underlying poor health of these patients, or to a combination of these two factors is uncertain. The findings in this study prompt us to recommend that all patients who receive amiodarone undergo complete ophthalmologic examinations, including careful evaluation of the ocular fundus regularly during such therapy. Appearance of optic neuropathy is probably a relative indication for discontinuing the use of the drug, in the hopes of avoiding bilateral involvement or perhaps recovering vision. The risks of complications of amiodarone treatment must be weighed against the benefit of therapy in patients whose lives are threatened by cardiac arrhythmias. On the basis of this study, the benefits of treatment seem to outweigh the small risk of optic neuropathy. No randomized study has been undertaken to determine the true incidence of complications associated with this medication and at this time could not be justified.

UR - http://www.scopus.com/inward/record.url?scp=0023190507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023190507&partnerID=8YFLogxK

M3 - Article

C2 - 3600041

AN - SCOPUS:0023190507

VL - 62

SP - 702

EP - 717

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -